MycoTherapy
Bacteria-based LCOR therapy in lung metastasis and rational design of co-stimulatory molecules.
Principal Investigator/s
Field / Programme
Systems and Synthetic Biology
Systems and Synthetic Biology
Summary
The lung ranks as the second most prevalent site for metastatic cancer occurrences. Despite the growing prominence of immunotherapy, a substantial proportion of lung cancer patients do not respond. Preclinical novel approaches aimed at circumventing resistance to immunity-based treatments involve harnessing the immunogenic effects of the protein LCOR combined with immunotherapy. However, systemic administration of immunotherapy is associated with potentially serious autoimmune side effects. This project will use a non-pathogenic engineered human lung bacterium for local delivery of LCOR and co-stimulatory molecules.
The lung ranks as the second most prevalent site for metastatic cancer occurrences. Despite the growing prominence of immunotherapy, a substantial proportion of lung cancer patients do not respond. Preclinical novel approaches aimed at circumventing resistance to immunity-based treatments involve harnessing the immunogenic effects of the protein LCOR combined with immunotherapy. However, systemic administration of immunotherapy is associated with potentially serious autoimmune side effects. This project will use a non-pathogenic engineered human lung bacterium for local delivery of LCOR and co-stimulatory molecules.
Start: 01/11/2024 End: 31/10/2027
Total Budget: 1.000.000,79
CRG Budget: 597.950,79
Funded by:
